1. Home
  2. SYRE vs BLCO Comparison

SYRE vs BLCO Comparison

Compare SYRE & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Spyre Therapeutics Inc.

SYRE

Spyre Therapeutics Inc.

HOLD

Current Price

$71.71

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Logo Bausch + Lomb Corporation

BLCO

Bausch + Lomb Corporation

HOLD

Current Price

$16.08

Market Cap

5.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYRE
BLCO
Founded
2013
1853
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ophthalmic Goods
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.9B
IPO Year
2015
2022

Fundamental Metrics

Financial Performance
Metric
SYRE
BLCO
Price
$71.71
$16.08
Analyst Decision
Strong Buy
Buy
Analyst Count
12
11
Target Price
$85.08
$18.45
AVG Volume (30 Days)
1.3M
381.1K
Earning Date
05-08-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$5,101,000,000.00
Revenue This Year
N/A
$8.65
Revenue Next Year
N/A
$5.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
6.47
52 Week Low
$12.29
$10.85
52 Week High
$76.00
$18.92

Technical Indicators

Market Signals
Indicator
SYRE
BLCO
Relative Strength Index (RSI) 62.72 46.44
Support Level $30.39 $14.39
Resistance Level $74.92 $17.11
Average True Range (ATR) 4.18 0.49
MACD -0.78 0.01
Stochastic Oscillator 43.70 37.90

Price Performance

Historical Comparison
SYRE
BLCO

About SYRE Spyre Therapeutics Inc.

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

About BLCO Bausch + Lomb Corporation

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Share on Social Networks: